Versor Investments LP Acquires 2,255 Shares of Edwards Lifesciences Co. (NYSE:EW)

Versor Investments LP lifted its position in Edwards Lifesciences Co. (NYSE:EW) by 102.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,455 shares of the medical research company’s stock after acquiring an additional 2,255 shares during the quarter. Versor Investments LP’s holdings in Edwards Lifesciences were worth $294,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 1.1% in the first quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after acquiring an additional 600,994 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Edwards Lifesciences by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after acquiring an additional 809,605 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Edwards Lifesciences by 57.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after acquiring an additional 2,390,137 shares in the last quarter. AustralianSuper Pty Ltd raised its holdings in shares of Edwards Lifesciences by 17.8% in the third quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after acquiring an additional 494,604 shares in the last quarter. Finally, Ownership Capital B.V. raised its holdings in shares of Edwards Lifesciences by 1.2% in the third quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company’s stock valued at $197,509,000 after acquiring an additional 34,597 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $67.76 on Friday. The business’s 50 day moving average price is $67.42 and its 200 day moving average price is $76.37. The firm has a market cap of $39.96 billion, a P/E ratio of 9.58, a P/E/G ratio of 3.74 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the company posted $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Analyst Ratings Changes

EW has been the subject of several recent research reports. Citigroup decreased their price objective on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a report on Tuesday, October 1st. Stifel Nicolaus cut their target price on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Piper Sandler cut their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Royal Bank of Canada cut their target price on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and an average target price of $75.67.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The trade was a 4.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,250 shares of company stock valued at $2,744,438. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.